NCT06081153View on ClinicalTrials.gov

Mechanistic Clinical Trial of PCSK9 Inhibition for AAA

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 1, 2026

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Abdominal Aortic Aneurysm
Interventions
DRUG

Evolocumab

See arm description.

DRUG

Placebo

See arm description.

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Amgen

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT06081153 - Mechanistic Clinical Trial of PCSK9 Inhibition for AAA | Biotech Hunter | Biotech Hunter